Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors from the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances analyze observed that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By https://camillae531gjk3.activosblog.com/profile